The cystic fibrosis drug Trikafta helps roughly 90 percent of people who have the deadly genetic disease. The drug enables patients to live a healthy life, start families, and think of a future.

BOSTON, December 20, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor ...

The cystic fibrosis drug Trikafta helps roughly 90 percent of people who have the deadly genetic disease. The drug enables patients to live a healthy life, start families, and think of a future.

TRIKAFTA ORAL GRANULES prescription and dosage information for physicians and ... diarrhea, rash, ALT/AST increased, nasal congestion, blood CPK increased, rhinorrhea, rhinitis, influenza ...

Trikafta’s sticker price is more than $300,000 a year. Insurance typically covers most of that cost—minus what can be significant co-pays and deductibles—and Vertex offers co-pay assistance.

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta, sending shares down 2.5% after the bell.

Trikafta, taken as three tablets a day, is the most powerful and widely used of Vertex’s four cystic fibrosis medications.With a list price of over $322,000 annually in the United States, it is ...

BOSTON, September 26, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first accepted medical presentations of the Phase 3 data on the investigational once daily ...

New limits on prescription drug prices could help millions afford life-saving drugs 03:42. For people with cystic fibrosis, like Sabrina Walker, Trikafta has been a life-changer.

But access to Trikafta is now at risk for several hundred people with CF, because of what some might consider to be good intentions. advertisement. Frustrated with rising health care costs, ...

Patients in the Alyftrek groups of both trials also experienced more improved sweat chloride concentrations vs. patients in the Trikafta groups at the 24-week mark (least squares mean treatment ...

Colorado’s new prescription drug review board decided that a medication costing more than $200,000 a year doesn’t qualify as “unaffordable,” based on the drug’s benefits to patients and ...